Salute e Benessere

Casino Group Communication

Not for publication, release, or distribution directly or indirectly in the United States, Canada, Australia or Japan. This press release is not an advertisement nor a prospectus within the meaning of Regulation (EU) 2017/1129Completion of the transactions involving Casino's share capital provided for in Casino's accelerated safeguard planSuspension of trading in Casino shares on 27 March 2024 Paris, 25 March 2024As part of the financial restructuring of Casino,...
Nasdaq GlobeNewswire
25/03/2024

Clinical Trial Supply & Logistics Market Projected to Reach $41.04 billion by…

"Global Growth Trends in Clinical Trial Supply & Logistics: Navigating Challenges, Driving Innovation" "Global Growth Trends in Clinical Trial Supply & Logistics: Navigating Challenges, Driving Innovation" Clinical trial supply and logistics (CTSL) is a critical backbone for conducting clinical studies worldwide, providing essential services, including planning, storing, managing, and distributing clinical trial materials (CTMs). These CTMs include investigational…
PR Newswire
25/03/2024

Foreløbige tal for 2023 og finansielle forventninger til 2024

Revisionen af selskabets årsrapport for 2023 er ikke afsluttet. Årsrapporten offentliggøres på onsdag den 27. marts 2024 i henhold til selskabets finanskalender. Selskabet har opnået følgende foreløbige resultater for 2023:Negativt driftsresultat på DKK 27 mio. hvilket er marginalt bedre end årets forventninger om et negativt driftsresultat på DKK 30-35 mio.Likvidbeholdningen ultimo 2023 var DKK 11 mio., hvilket er marginalt bedre end årets forventninger om DKK 6-10 mio. Guidance...
Nasdaq GlobeNewswire
25/03/2024

Radiopharmaceuticals Market to Reach $11.6 Billion by 2034 as Cancer Treatment…

Although the market is still in its nascent stages, it is slated to pick up some pace in the coming decade. With industry giants, both public as well as private, pouring billions of dollars into the development of novel radio nucleotide-including treatments, the global valuation is very likely to reach US$ 11,635 million by 2034. Although the market is still in its nascent stages, it is slated to pick up some pace in the coming decade. With industry giants, both public as well as private,...
PR Newswire
25/03/2024

Gedeon Richter Selects Trial Interactive for Clinical Trial Management

Based in Budapest, Hungary, Gedeon Richter is an innovation-driven specialty pharmaceutical company that aspires to improve the quality of human life by developing and manufacturing medications across a range of therapeutic areas. The company's product portfolio spans women's healthcare, neuropsychiatry, rheumatology, osteoporosis, cardiology, blood, diabetes, and CNS. Based inBudapest, Hungary, Gedeon Richter is an innovation-driven specialty pharmaceutical company that aspires to improve...
PR Newswire
25/03/2024

GenieMD Awarded Frost & Sullivan's 2024 Company of the Year Award for Pioneering…

GenieMD's platform stands out for its ability to empower healthcare providers and extend care beyond traditional settings into patients' homes. The company delivers personalized treatment plans and early intervention through its robust suite of services, including telehealth, remote patient monitoring, chronic care management, remote therapeutic monitoring, and behavioral health. This innovative approach significantly improves patient outcomes and aligns with the growing trend toward home-based…
PR Newswire
25/03/2024

Midea Unveils Next-Generation Appliances at European Trade Conference 2024…

Midea TastePro Oven Midea TastePro Oven Midea 2.0 Built-in Oven Midea's appliances are designed to provide cooking assistance for Europeans in their homes. By offering outstanding control, flexibility, and performance, they make traditional routines into comfortable, efficient, and versatile cooking experiences. Midea aims to showcase its leadership in delivering top-quality kitchen appliances that meet European consumers' evolving needs and preferences, offering new possibilities...
PR Newswire
25/03/2024

Early Detection Surge: In-Vitro Diagnostics Kits to Reach US$18.8 Billion as…

Download the Sample PDF report to explore key market insights and trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-13548 Download the Sample PDF report to explore key market insights and trends:https://www.futuremarketinsights.com/reports/sample/rep-gb-13548 The main market driver for the subject market is the increasing prevalence of chronic diseases. Especially after the pandemic outbreak, the necessity of test kits to check physical health has surged. Moreover,...
PR Newswire
25/03/2024

LILYSILK and NBCF Partner to Launch Caring Collection, Elevating Breast Cancer…

The Caring Collection features exquisite silk items designed to offer solace and support in everyday life. Each product from this line – Hope's Comfort Pillowcase, Eternal Hope Scrunchie, Hopeful Dreams Sleep Eye Mask, and The Hope's Embrace Sleep Set – is a testament to LILYSILK's commitment to quality, comfort, and community care. The collection serves as a symbol of strength, unity, and hope so no one faces breast cancer alone. The Caring Collection features exquisite silk items designed…
PR Newswire
25/03/2024

TNO launches Peregrion to boost market impact of its technology that accelerates…

Peregrion will build on TNO's legacy of generating early human microtracer data from absorption, distribution, metabolism and excretion studies. TNO has optimised the process through the years, for instance by developing a sample preparation technology to enable the detection, identification and quantification of all human metabolites as early as clinical phase 1. Currently, a large number of top-20 pharmaceutical companies are using TNO's AMS technology to advance their medicine development…
PR Newswire
25/03/2024

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; March 25, 2024 – Genmab A/S (Nasdaq: GMAB).On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024.The following transactions were executed under the program from March 18, 2024 to March 22, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK) ...
Nasdaq GlobeNewswire
25/03/2024

AIM ImmunoTech Announces Publication of Positive Findings from a Study…

Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen AIM ImmunoTech Inc.(NYSE American: AIM) (“AIM”) today announced the publication of new data analysis from a long-term Early Access Program (“EAP”) studying the company's drug Ampligen® (rintatolimod) for the treatment of advanced pancreatic ductal adenocarcinoma (“PDAC”). The manuscript titled “Rintatolimod in Advanced Pancreatic Cancer enhances Anti-Tumor Immunity...
Nasdaq GlobeNewswire
25/03/2024

StickIt Technologies Announces Major Breakthrough in Cannabinoid Technology

Eli Ben Haroosh, CEO, commented, "Today marks a monumental day for StickIt Technologies Inc. as we unveil a groundbreaking advancement in cannabinoid consumption. Our new StickIt SipIt straw is not only a testament to innovation but also a step forward in making cannabinoid use seamless, enjoyable, and efficient. This development eradicates the hassle of traditional consumption methods, offering rapid, discreet, and precise dosing without compromising taste or experience. It's a...
PR Newswire
25/03/2024

To Bolster Global Efforts in Combating Antibiotic-Resistant Bacteria KFSH&RC…

RIYADH, Saudi Arabia, March25, 2024(GLOBE NEWSWIRE) -- In a ground-breaking development, scientists at King Faisal Specialist Hospital and Research Centre (KFSH&RC) have identified a new species of bacteria, referred to as "Stenotrophomonas Riyadhensis" through the application of whole-genome sequencing (WGS) technology. This discovery signifies a major advancement in understanding how bacteria interact with existing drugs, paving the way for innovative therapeutic strategies...
Nasdaq GlobeNewswire
25/03/2024

IMC Expects Accelerated Growth in Germany from the Country's Groundbreaking…

The regulatory rescheduling of cannabis along with the expected market growth, provides IMC with a unique growth opportunity. In Germany, IMC: The regulatory rescheduling of cannabis along with the expected market growth, provides IMC with a unique growth opportunity. InGermany, IMC: "We have been working toward this moment for the last 4 years," said Richard Balla, CEO of IMC Germany. "We have the entire infrastructure in house. We are EU-GMP certified to repack bulk. We have…
PR Newswire
25/03/2024

triLift By Lumenis Receives Medical Device License from Health Canada, Launches…

Our muscles play a crucial role in defining facial structure, and as we age, we lose facial muscle mass, leading to sagging jawlines, droopy cheekbones, the appearance of mouth folds and baggy lower eyelids. triLift is a game-changing advancement in the facial aesthetics market with its novel Dynamic Muscle Stimulation (DMSt™) technology complemented by RF and RF microneedling. By specifically targeting the facial muscles, triLift effectively treats structure, contour, and texture, resulting in…
PR Newswire
25/03/2024

Sirtex Medical Appoints Matt Schmidt as New Chief Executive Officer and Board of…

"I am confident Matt will advance Sirtex's vision of providing minimally invasive cancer and embolization therapies to more patients around the globe," said Dr. Weikun Tang, chairman of Grand Pharmaceutical Group Co., Ltd. "Matt's performance-driven leadership capabilities, as well as his commitment to partner with physicians to provide patients with innovative solutions, positions him as the right person to lead Sirtex into its next phase of growth. We are excited to work closely…
PR Newswire
25/03/2024

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 25 March 2024– On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2023. Under the...
Nasdaq GlobeNewswire
25/03/2024

Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial…

– The independent data monitoring committee (IDMC) recommended the continuation of VIRAGE,the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma (PDAC), with no safety concerns raised - - VIRAGE remains on track to complete enrollment in the first half of 2024-- As of December 31, 2023, Theriva Biologics reports $23.2 million in cash, which is expected to provide runway into the first quarter of 2025 -- Conference...
Nasdaq GlobeNewswire
25/03/2024

Adagio Medical Announces CE Mark approval of VT Cryoablation System, Plans for…

"We are encouraged by the commercial availability of the dedicated VT ablation system in our European centers, as it shows promise for patients with ventricular arrhythmias," said Professor Dr. KR Julian Chun of Cardiovascular Center Bethanien ("CCB") in Frankfurt, Germany. "The current VT ablation practice has evolved around generic catheter tools available to the clinicians, with all associated trade-offs, limiting, to an extent, how broadly we offer ablations to a…
PR Newswire
25/03/2024

Wyeth launches China's first infant formula with two types of HMOs, leading the…

Ms. Shiela Qiu, Regional Business Head, Wyeth Nutrition Greater China Region, stated, "We are thrilled to achieve another milestone in the Chinese infant nutrition market. Wyeth Nutrition's dominant position in the global human milk oligosaccharide (HMO) industry is further evidenced by the introduction of China's first HMO-infused infant formula, which contains two different kinds of HMOs. Wyeth Nutrition is dedicated to fostering the superior growth of the Chinese infant nutrition market…
PR Newswire
25/03/2024

Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in…

Bagsværd, Denmark, and Hannover, Germany, 25 March, 2024– Novo Nordisk and Cardior Pharmaceuticals today announced that Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial milestones are achieved. Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. The company's therapeutic...
Nasdaq GlobeNewswire
25/03/2024

Novo Nordisk A/S - Articles of Association 2024

Novo Nordisk's Articles of Association 2024 Attachment Articles of Association 21 Mar 2024
Nasdaq GlobeNewswire
25/03/2024

Invitation to presentation of Essity's interim report for the first quarter 2024

Contact information for conference call with the possibility to ask questions:UK: +44 (0) 33 0551 02 00 USA: +1 786 697 35 01SWE: +46 (0)8 505 204 24Please call in well in advance of the start of the presentation. Indicate: "Essity". Contact information for conference call with the possibility to ask questions: UK: +44 (0) 33 0551 02 00 USA : +1 786 697 35 01 SWE: +46 (0)8 505 204 24 Please call in well in advance of the start of the presentation. Indicate…
PR Newswire
25/03/2024
Altri  Comunicati